Video
Is Five Years Long Enough?
Panelists see the 5-year period of the Enhancing Oncology Model as reasonable; they would like see some progress toward permanent value-based payment structures.
EP: 1.No Successor to OCM Would Disappoint
EP: 2.CMMI Open to Feedback, but EOM Out of the Blue
EP: 3.Some Practices That Did Not Do OCM Are Applying
EP: 4.Seven Tumor Types: Pros and Cons
EP: 5.A Model That Is Built to “Win”
EP: 6.Addressing Health Equity and Social Needs
EP: 7.Is Five Years Long Enough?
EP: 8.Changes to MEOS and Barriers to Entry
EP: 9.Small Practices and Dual Risk: Considerations and Approaches
EP: 10.Does Pooling Make Sense?
EP: 11.What Would You Change About the EOM?
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates and the outgoing president of Community Oncology Alliance, sees 5 years of the EOM as a prelude to a more permanent reimbursement structure for addressing patients' social needs. Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, hopes the EOM tracks progress in the ASCO Oncology Medical Home. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, would like to see more key performance indicators added to the EOM.
